15 stories found
An analysis explores whether Abbott Laboratories' Instinct Sensor can provide a significant competitive advantage over MiniMed Group. The article delves into the potential market impact and technological superiority of the sensor.
Wall Street analysts have released a range of research calls, including updates on Scotts Miracle-Gro, Colgate-Palmolive, Townsquare Media, Concentrix, Oxford Industries, Dime Community Bancshares, Buckle, UDR, Mid-America Apartment Communities, Winnebago, BankUnited, Smithfield Foods, THOR Industries, JPMorgan Chase, and a 'Buy' rating for Grab Holdings from Barclays.
Medtronic has revised its earnings outlook for 2026 downwards, attributing the change to recent updates concerning its MiniMed products.
MiniMed, a subsidiary of Medtronic, has priced its initial public offering of $560 million at $20 per share.
Medtronic's diabetes unit, MiniMed, is reportedly seeking $784 million in its upcoming US Initial Public Offering.
Citi has cut its target for Medtronic (MDT), while Stifel has lowered its outlook for the company, following the recent MiniMed IPO.
Gas prices in the US have eclipsed $4 a gallon, reaching their highest level since 2022 and continuing to rise rapidly, as the Iran war disrupts global energy supply through the Strait of Hormuz.
Investors are evaluating whether to buy MMED stock following the recent initial public offering of MiniMed.
Medtronic's diabetes unit, MiniMed, is reportedly seeking a valuation of $7.9 billion as it prepares for a US initial public offering.
Stifel has lowered its price target for Medtronic (MDT) to $95, attributing the adjustment to the anticipated effects of the MiniMed IPO.
Bank of America has initiated coverage of MiniMed with a 'Buy' rating, citing a positive outlook driven by the company's pipeline of products and potential for growth.
Medtronic's diabetes unit, MiniMed, experienced a decline in its stock value on its trading debut.
Medtronic's diabetes business unit, MiniMed, is reportedly planning an Initial Public Offering (IPO) in the United States, aiming to raise $784 million.
Medtronic's diabetes unit, MiniMed, is reportedly seeking to raise up to $784 million through an initial public offering (IPO) in the U.S. market.